Literature DB >> 1810594

Access of peripherally administered DuP 753 to rat brain angiotensin II receptors.

K F Song1, J L Zhuo, F A Mendelsohn.   

Abstract

The in vivo access of the nonpeptide angiotensin II (Ang II) antagonist, DuP 753 (10 mg kg-1, i.v.), to Ang II receptors of rat brain was investigated by in vitro autoradiography with [125I]-[Sar1, Ile8] Ang II as a ligand. DuP 753 markedly inhibited the binding to sites which contain exclusively AT1 receptors both outside and within the blood brain barrier, such as the circumventricular organs, paraventricular hypothalamic nucleus, median preoptic nucleus and nucleus of the solitary tract. However, binding to other nuclei containing AT2 receptors was not significantly inhibited. These results demonstrate that DuP 753 and/or its active metabolite readily cross the blood brain barrier in vivo and selectively inhibit binding to AT1 receptors in specific brain nuclei.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810594      PMCID: PMC1908825          DOI: 10.1111/j.1476-5381.1991.tb12503.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

2.  Non-peptide angiotensin II receptor antagonists discriminate subtypes of 125I-angiotensin II binding sites in the rat brain.

Authors:  D R Gehlert; S L Gackenheimer; J K Reel; H S Lin; M I Steinberg
Journal:  Eur J Pharmacol       Date:  1990-10-02       Impact factor: 4.432

3.  Evidence for the presence of angiotensin II-type 1 receptors in brain.

Authors:  J K Wamsley; W F Herblin; M E Alburges; M Hunt
Journal:  Brain Res Bull       Date:  1990-09       Impact factor: 4.077

4.  Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist.

Authors:  N M Barnes; B Costall; M E Kelly; D A Murphy; R J Naylor
Journal:  Neuroreport       Date:  1990-09       Impact factor: 1.837

5.  Identification of angiotensin II receptor subtypes.

Authors:  A T Chiu; W F Herblin; D E McCall; R J Ardecky; D J Carini; J V Duncia; L J Pease; P C Wong; R R Wexler; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  1989-11-30       Impact factor: 3.575

6.  Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

7.  Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm.

Authors:  N M Barnes; S Champaneria; B Costall; M E Kelly; D A Murphy; R J Naylor
Journal:  Neuroreport       Date:  1990 Nov-Dec       Impact factor: 1.837

8.  Angiotensin II receptor subtypes in rat brain.

Authors:  K Song; A M Allen; G Paxinos; F A Mendelsohn
Journal:  Clin Exp Pharmacol Physiol       Date:  1991-02       Impact factor: 2.557

  8 in total
  8 in total

1.  Angiotensin AT1 receptor blockade abolishes the reflex sympatho-excitatory response to adenosine.

Authors:  G A Rongen; S C Brooks; S i Ando; B L Abramson; J S Floras
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

2.  The role of the renin-angiotensin system in the renal response to moderate hypoxia in the rat.

Authors:  M Neylon; J Marshall; E J Johns
Journal:  J Physiol       Date:  1996-03-01       Impact factor: 5.182

Review 3.  Clinical pharmacokinetics of losartan.

Authors:  Domenic A Sica; Todd W B Gehr; Siddhartha Ghosh
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze.

Authors:  R P Dennes; J C Barnes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

6.  Binding of angiotensin antagonists to rat liver and brain membranes measured ex vivo.

Authors:  F H Marshall; S A Clark; A D Michel; J C Barnes
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

7.  Involvement of Type 1 Angiontensin II Receptor (AT1) in Cardiovascular Changes Induced by Chronic Emotional Stress: Comparison between Homotypic and Heterotypic Stressors.

Authors:  Willian Costa-Ferreira; Jonas O Vieira; Jeferson Almeida; Lucas Gomes-de-Souza; Carlos C Crestani
Journal:  Front Pharmacol       Date:  2016-08-18       Impact factor: 5.810

8.  Circadian Differences in the Contribution of the Brain Renin-Angiotensin System in Genetically Hypertensive Mice.

Authors:  Kristy L Jackson; Francine Z Marques; Kyungjoon Lim; Pamela J Davern; Geoffrey A Head
Journal:  Front Physiol       Date:  2018-03-19       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.